Clinical Trial

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-10-13; most recent amendment 2026-01-27.
Status change: Recruiting → Active, Not Recruiting 2025-11-21
Status change: Not Yet Recruiting → Recruiting 2024-04-03
Trial Details
NCT Number NCT05583149
Lead Sponsor Patrick C. Johnson, MD
Collaborators: AstraZeneca
Conditions Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos +5 more
Enrollment 28 participants
Start Date 2023-03-01
Primary Completion 2024-11-23 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-29